Piper Sandler Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $53.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price lifted by Piper Sandler from $52.00 to $53.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. Piper Sandler’s target price points to a potential upside of 0.38% from the company’s current price.

Several other research firms have also weighed in on HALO. JMP Securities lifted their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $61.44.

Halozyme Therapeutics Stock Down 1.8 %

NASDAQ:HALO opened at $52.80 on Friday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The company’s fifty day moving average price is $50.14 and its 200-day moving average price is $54.02. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The firm has a market capitalization of $6.72 billion, a P/E ratio of 17.48, a PEG ratio of 0.44 and a beta of 1.24.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.70% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Halozyme Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after acquiring an additional 30,901 shares during the last quarter. Congress Asset Management Co. raised its stake in Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock worth $139,298,000 after purchasing an additional 1,988,238 shares during the period. Handelsbanken Fonder AB boosted its holdings in Halozyme Therapeutics by 76.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Halozyme Therapeutics by 12.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Halozyme Therapeutics by 9.7% in the 2nd quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company’s stock valued at $43,002,000 after buying an additional 72,544 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.